The Barrick Gold April 48 call option (ABX + DR) and the Agnico-Eagle Mines January 65 call option (AEM + AM) are a both a buy here. So, too, is our equity position in Gabriel Resources (GBU.TO, GBRFF). The election results in Romania were extremely close with the sitting President, Traian Basescu, winning a second term. With the EU and IMF breathing down its neck, the government will be under intense pressure to reform the Romanian economy, which should help Gabriel move forward with its mining project. Crude oil’s weakness has been no help for Transocean January 95 call option (RIG + AS). We’re not ready to give up on the position, but we’re downgrading it to a hold this week. Our Amylin January 12.50 call option (AQM + AV) is a hold. The stock has a lot going for it, and should rise sharply on FDA approval for a long acting release formula of its diabetes drug Byetta, which could come shortly. Retail sales data coming in are showing an improvement over last year’s dismal results, but they still leave a lot to be desired. American Express (AXP) has surrendered several points with investors reassessing the stock’s recent run. Continue to hold your American Express January 36 put option (ABZ + MD). Read More
Our seasoned team of analysts continually monitors investment opportunities around the world, to provide investors with the widest possible array of money-making ideas.
Analyst Articles
Markets the world over had a scare last week when Dubai World, the Persian Gulf-based real estate outfit that is presumably backed by the emirate of Dubai sought to defer payment on its debt for six months. Read More
This morning we closed out the Barrick Gold January 37.50 call (ABX + AU) for a gain of 196 percent in less than two months. We rolled that position into the Barrick Gold April 48 call option (ABX + DR) for more leverage. The option is a buy up… Read More
Sell to close your Barrick Gold January 37.50 call option (ABX + AU) at the money. Buy to open the Barrick Gold April 48 call (ABX + DR). Pay no more than $4.10 per contract. Read More
Bagging profits should be a simple lay-up for the bulls during this holiday shortened trading week. Microscopic short-term interest rates, with 3-month Treasury bills now yielding a scant 0.045 percent, and continued softness in the U.S. Read More
The Barrick Gold (ABX) January 37.50 call option (ABX + AU) is a hold as the option is well in the money at this time. The Agnico-Eagle Mines January 65 call option (AEM + AM) is a buy up to $3.30. Gabriel Resources (GBU.TO, GBRFF), our long-term gold equity is a buy for new clients at the current price. Transocean (RIG) has pulled back in price and is tracking the price of oil fairly closely. The implied volatility on our Transocean January 95 call option (RIG + AS) has come down as well, further hurting our position. We still rate it a buy for new clients at its current price, however. Amylin Pharmaceuticals (AMLN) is getting a boost today compliments of a brokerage upgrade. We think the stock is worth far more than it’s selling for today and we’ll realize a higher price before expiration of our Amylin January 12.50 call option (AQM + AV). The option is a buy on a dip to $1.15 per contract. Williams Sonoma (WSM) produced better-than-expected quarterly results last week, but the company’s revised guidance for the fourth quarter merely brought it in line with Wall Street forecasts. The stock wasn’t able to gain much traction on the news and in light of what we’re seeing in the economy we’re willing to hold our short sale for a while longer. New clients can sell the stock short here. Read More
Investors’ appetite for risk just keeps getting stronger. Unfortunately, that’s not necessarily a good thing. And while this trend may continue through the upcoming holiday season, the risk of a major setback remains quite high. Read More
Our Barrick Gold (ABX) January 37.50 call option (ABX + AU) is surrendering some of its gain today, but we’ll continue to hold. The Agnico-Eagle Mines January 65 call option (AEM + AM) is a buy up to $3.30. Gabriel Resources (GBU.TO, GBRFF), has been the big winner in the past week. The stock has soared on word that the company has done a private placement with an investor with extensive dealings in Romania and who has excellent connections there to help move Gabriel’s Rosia Montana project toward production. This is a long-term position of ours and we still recommend the shares for purchase. Our long trade in the energy patch, the Transocean January 95 call option (RIG + AS), is a buy at its current price. We’ve long seen Amylin Pharmaceuticals (AMLN) as a takeover candidate, although that wasn’t what prompted our recommendation of the Amylin Pharmaceuticals January 12.50 call option (AQM + AV). Eli Lilly has been seen the logical suitor because of the close ties between the two and Lilly’s position in diabetes treatments. This week, speculation has turned to Merck as a possible buyer after company’s CEO said (without naming names) that he is interested in acquiring a biotech outfit of Amylin’s size and he likes the diabetes space. Our option is a buy on a dip to $1.15 per contract. Read More
As is the case leading up to every Olympiad, the amount of economic activity the 2010 Vancouver and Whistler Winter Olympic Games will generate has been one of the two central questions ever since a bid was first proposed, the other, of course, being the question of how much they’ll cost Canadian taxpayers. Read More
One thing’s for sure about this business, there’s never a dull moment in the markets. No sooner did it look like equities were breaking down than they staged a big turnaround last week. Together with yesterday’s trading they managed to recover much of the ground they lost in the prior few weeks. Read More